hyaluronidase + insulin lispro

This is a combination of hyaluronidase (specifically recombinant human hyaluronidase, often rHuPH20) and insulin lispro, a rapid-acting insulin analog. The rationale for combining these agents is that hyaluronidase enzymatically degrades hyaluronic acid in the subcutaneous tissue, increasing tissue permeability and thereby accelerating the absorption and onset of action of co-administered drugs such as insulin lispro. Clinical studies have shown that co-administration or formulation with recombinant human hyaluronidase reduces variability in pharmacokinetics, accelerates absorption, increases early exposure to insulin, and shortens duration of action compared to insulin alone. This can result in more physiologic postprandial glucose control for people with diabetes. The safety profile of the combination is comparable to that of insulin lispro alone[2][4][5].

Brand names

Lispro-PH20Lispro-PH-20Lispro-PH 20

Other names

lispro-PH20lispro-PH-20lispro-PH 20